Study shows breast cancer vaccination may be promising
Jan 31, 2012
A study conducted by researchers from Perelman School of Medicine at the University of Pennsylvania found that a new breast cancer vaccination may be promising, after 85 percent of patients with ductal carcinoma in situ appeared to have a sustained immune reaction after being vaccinated.
The researchers studied 27 women with the ductal carcinoma in situ type of breast cancer. They were given the vaccinations four times a month and discovered that the disease was eliminated or there was a decrease in tumors in the majority of patients.
"We are continuing to see this pattern in our second, ongoing trial," said study leader Dr. Brian Czerniecki, surgical director of the Rena Rowan Breast Center at the University of Pennsylvania.
According to the American Cancer Society, one in eight women in the U.S. will be diagnosed with breast cancer at some point during their lifetime. Not only is it the second most common form of cancer among women, behind skin cancer, but it is also the second leading cause of cancer-related death among women, following only lung cancer.